Liberia Gets Ebola Drug; Ponders Who Should Get It
Liberian officials faced a difficult choice Thursday: deciding which handful of Ebola patients will receive an experimental drug that could prove life-saving, ineffective or even harmful.
ZMapp, the untested Ebola drug, arrived in the West African country late Wednesday. A day later, no one had yet received the treatment, which officials said would go to three people.
The government had previously said two doctors would receive the treatment, but it was unclear who else would. Information Minister Lewis Brown said Thursday it would probably be another health care worker.
These are the last known doses of ZMapp left. The San Diego-based company that developed it has said it will take months to build up even a modest supply.
The Ebola outbreak was first identified in March in Guinea. It has since spread to Liberia, Sierra Leone and Nigeria, killing more than 1,060 of the 1,975 people sickened, according to the World Health Organization. There is no licensed treatment for Ebola, a virus transmitted by contact with bodily fluids like blood, sweat, urine, diarrhea and vomit.
The outbreak has overwhelmed the already strained health systems in West Africa and raised questions about whether authorities are doing enough to respond.
On Thursday, the U.S. State Department ordered families of embassy personnel to leave Sierra Leone because of concerns that the crisis would make it difficult to get treatment for even routine health problems.
Meanwhile, police in riot gear dispersed an angry crowd Thursday in the Liberian capital of Monrovia who blocked city buses to protest delays in clearing away the infectious body of an Ebola victim.
President Barack Obama spoke by phone Thursday about the Ebola outbreak with Liberian President Ellen Johnson Sirleaf and in another call with President Ernest Bai Koroma of Sierra Leone. The White House said Obama expressed his condolences for the hundreds who have died in both countries and underscored the U.S.'s commitment to work with West African nations and U.N. agencies to contain the outbreak.
The outbreak has sparked an international debate over the ethics of giving drugs that have not yet been tested to the sick and of deciding who should get the drugs. So far, only two Americans and one Spaniard have received ZMapp. The Americans are improving — but it is unclear what role the drug has played. The Spaniard died within days.
Now Liberian officials are facing those questions. In this outbreak, over 50 percent of those sickened with Ebola have died, according to the U.N. health agency.
"The criteria of selection is difficult, but it is going to be done," said Dr. Moses Massaquoi, who helped Liberia obtain the drug from Mapp Biopharmaceutical. "We are going to look at how critical people are. We are definitely going to be focusing on medical staff."
He added people past the "critical phase" who looked likely to survive would not be chosen.
Massaquoi said there was only enough of the drug to treat three people. Treatment will be staggered, so doctors can observe the effects in one patient before moving on to the next. Late Thursday, he said the treatment had not yet started.
Arthur Caplan, director of medical ethics at NYU Langone Medical Center, said the choice of who to treat would have to balance helping the largest number of people with learning the most from the treatments.
He said the question is not "whose life do we save?" but "who gets the chance to be experimented on?"
選擇“Disable on www.wenxuecity.com”
選擇“don't run on pages on this domain”
